WO1998006431A3 - Procede de traitement des diabetes - Google Patents
Procede de traitement des diabetes Download PDFInfo
- Publication number
- WO1998006431A3 WO1998006431A3 PCT/US1997/014448 US9714448W WO9806431A3 WO 1998006431 A3 WO1998006431 A3 WO 1998006431A3 US 9714448 W US9714448 W US 9714448W WO 9806431 A3 WO9806431 A3 WO 9806431A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treating diabetes
- diabetes
- compositions
- methods
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU40708/97A AU4070897A (en) | 1996-08-16 | 1997-08-15 | Method for treating diabetes |
EP97938359A EP0859633A2 (fr) | 1996-08-16 | 1997-08-15 | Procede de traitement des diabetes |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69892696A | 1996-08-16 | 1996-08-16 | |
US08/698,926 | 1996-08-16 | ||
US76029996A | 1996-12-04 | 1996-12-04 | |
US08/760,299 | 1996-12-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998006431A2 WO1998006431A2 (fr) | 1998-02-19 |
WO1998006431A3 true WO1998006431A3 (fr) | 1998-06-18 |
Family
ID=27106305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/014448 WO1998006431A2 (fr) | 1996-08-16 | 1997-08-15 | Procede de traitement des diabetes |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0859633A2 (fr) |
AU (1) | AU4070897A (fr) |
WO (1) | WO1998006431A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007202840B2 (en) * | 2001-01-09 | 2011-07-28 | Baylor Research Institute | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
JP5837730B2 (ja) | 2005-02-10 | 2015-12-24 | ベイラー リサーチ インスティテュートBaylor Research Institute | 抗インターフェロンアルファモノクローナル抗体及び使用方法 |
KR101687032B1 (ko) | 2008-05-07 | 2016-12-15 | 아고스 쎄라퓨틱스, 인코포레이티드 | 인간 인터페론-알파에 대한 인간화 항체 |
US20140242038A1 (en) * | 2011-10-11 | 2014-08-28 | The Trustees Of Columbia University In The City Of New York | Method for generating beta cells |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0034307A2 (fr) * | 1980-02-16 | 1981-08-26 | Hoechst Aktiengesellschaft | Procédé pour la préparation d'interféron de leucocytes humains |
WO1993004699A1 (fr) * | 1991-08-30 | 1993-03-18 | Genentech, Inc. | Procede therapeutique servant a traiter le diabete sucre insulinodependant |
EP0588177A2 (fr) * | 1992-09-03 | 1994-03-23 | YEDA RESEARCH AND DEVELOPMENT CO., Ltd. | Protéine se liant à l'interferon-alpha/beta, sa préparation et les compositions pharmaceutiques la contenant |
WO1996034096A1 (fr) * | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
-
1997
- 1997-08-15 WO PCT/US1997/014448 patent/WO1998006431A2/fr not_active Application Discontinuation
- 1997-08-15 EP EP97938359A patent/EP0859633A2/fr not_active Withdrawn
- 1997-08-15 AU AU40708/97A patent/AU4070897A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0034307A2 (fr) * | 1980-02-16 | 1981-08-26 | Hoechst Aktiengesellschaft | Procédé pour la préparation d'interféron de leucocytes humains |
WO1993004699A1 (fr) * | 1991-08-30 | 1993-03-18 | Genentech, Inc. | Procede therapeutique servant a traiter le diabete sucre insulinodependant |
EP0588177A2 (fr) * | 1992-09-03 | 1994-03-23 | YEDA RESEARCH AND DEVELOPMENT CO., Ltd. | Protéine se liant à l'interferon-alpha/beta, sa préparation et les compositions pharmaceutiques la contenant |
WO1996034096A1 (fr) * | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
Non-Patent Citations (1)
Title |
---|
STEWART ET AL.: "Induction of Type I Diabetes by Interferon-alpha in transgenic mice", SCIENCE, vol. 260, 25 June 1993 (1993-06-25), pages 1942 - 1946, XP002050198 * |
Also Published As
Publication number | Publication date |
---|---|
AU4070897A (en) | 1998-03-06 |
WO1998006431A2 (fr) | 1998-02-19 |
EP0859633A2 (fr) | 1998-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0717592A4 (fr) | Procede et composition de traitement du syndrome d'apathie-amotivation | |
ZA972929B (en) | Systems for the treatment of commingled wastes and methods for treating commingled wastes. | |
AU9040098A (en) | Compounds and method for the prevention and treatment of diabetic retinopathy | |
ZA977513B (en) | Skin tanning compositions and method. | |
AU5729098A (en) | Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes | |
HU9802721D0 (en) | Method and composition for the treatment and prevention of hyperuricemia | |
ZA991053B (en) | Method and composition for treatment of inflammatory conditions. | |
AUPM761094A0 (en) | Treatment of hides | |
EP1043983A4 (fr) | Tetracycline et/ou un ou plusieurs derives de tetracycline pour traiter, supprimer ou prevenir des maladies cerebrovasculaires du systeme nerveux | |
ZA967963B (en) | Compositions and methods of controlling harmful fungi. | |
AU2825295A (en) | Method for the treatment, prevention or minimization of hair loss | |
ZA985237B (en) | Novel method of treatment. | |
EP0630383A4 (fr) | Procedes de traitement des diabetes. | |
WO1998006431A3 (fr) | Procede de traitement des diabetes | |
ZA974421B (en) | Method of improving skin condition. | |
ZA972722B (en) | Method for prevention and treatment of viral infectious diseases. | |
ZA986365B (en) | Novel method of treatment. | |
ZA978257B (en) | Method of treatment of amyotrophic lateral sclerosis. | |
ZA977867B (en) | Method of treatment. | |
PL328925A1 (en) | Method of treating bipolar disorders | |
GB9625398D0 (en) | Method of treatment,manufacture,compositions and compounds | |
AU5265596A (en) | Composition and method for the treatment of premenstrual syndrome | |
ZA200007396B (en) | Method of treatment. | |
AUPM836794A0 (en) | Improved method and composition for the treatment of ulcers | |
ZA985117B (en) | Method of attenuating viruses. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997938359 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1997938359 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 98510086 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997938359 Country of ref document: EP |